Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 3, 2012, Pages 359-363

  Hwang, Janice J ^a   Wei, Jeffrey ^a   Abbara, Suhny ^a   Grinspoon, Steven K ^a   Lo, Janet ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; HIV; Osteoprotegerin; Receptor activator of nuclear factor kappa ligand

Indexed keywords

CALCIUM; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFSF11 PROTEIN, HUMAN;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANGIOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CORONARY ARTERY DISEASE; MIDDLE AGED; RADIOGRAPHY;

CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RANK LIGAND;

EID: 84864148444     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31826a6c16     Document Type: Article

References (24)

1. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179.
2. Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001;276:20659-20672.
3. Towler DA, Demer LL. Thematic series on the pathobiology of vascular calcification: an introduction. Circ Res. 2011;108:1378-1380.
4. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003.
5. Golledge J, McCann M, Mangan S, et al. Osteoprotegerin and osteopon-tin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-1641.
6. Anand DV, Lahiri A, Lim E, et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006;47:1850-1857.
7. Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99:513-518.
8. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care. 2006;29:1664-1666.
9. Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract. 2007;76:199-206.
10. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-633.
11. Crisafulli A, Micari A, Altavilla D, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond). 2005;109:389-395.
12. Schoppet M, Schaefer JR, Hofbauer LC. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation. 2003;107:e76; Author reply: e76.
13. Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116:385-391.
14. Lo J, Abbara S, Shturman L, et al. Increased prevalence of sub-clinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24: 243-253.
15. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocar-dial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92:2506-2512.
16. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003; 278:48251-48258.
17. Chakravarti A, Marceau AA, Flamand L, et al. Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab Invest. 2008;88:171-184.
18. Gibellini D, Borderi M, De Crignis E, et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol. 2007;79:1446-1454.
19. Brown TT, Ross AC, Storer N, et al. Bone turnover, osteoprotegerin/ RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther. 2011;16:1063-1072.
20. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(4 suppl):5-40.
21. Wang MW, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest. 2004;114:206-213.
22. Sandberg WJ, Yndestad A, Oie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque desta-bilization. Arterioscler Thromb Vasc Biol. 2006;26:857-863.
23. Findlay D, Chehade M, Tsangari H, et al. Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther. 2008;10:R2.
24. Bord S, Ireland DC, Beavan SR, et al. The effects of estrogen on osteopro-tegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 2003;32:136-141.